Drägerwerk

SDAX company Drägerwerk reported third-quarter earnings before interest and taxes of around €48 million, down from just under €57 million a year earlier; this figure includes customs refunds of €20.1 million. Revenue rose 2.1 percent to about €851 million, and order intake climbed 8.2 percent to €926 million. The annual forecast was confirmed. The share fell about 5 percent in after-hours trading to €109.60. » Mere på finanzen.net

The Drägerwerk preferred share is slightly under pressure but, after a strong rally, remains markedly higher than three years ago. A hypothetical investment of €1,000 three years ago would, including reinvested dividends (€1.80 on 9 May 2024, €2.03 on 12 May 2025, €2.27 on 11 May 2026), have grown to around €3,063, equivalent to a total return of about 206%. Without dividends the value would be about €2,785, so most of the gain comes from the price increase. Taxes, order costs and rounding effects were not taken into account in the calculation. » Mere på deraktionaer.de

The Drägerwerk preferred share is trading near its yearly high and sits well above the medium-term upward trend channel; the RSI signals slight overbought conditions. Fundamentally, the company is supported by two recent price-target increases, and a further raise was discussed internally. However, after a year-to-date gain of almost 70%, the stock would be vulnerable to a market correction or profit-taking. Technically, the medium-term trend currently runs roughly around €102 on the upside and around €83 on the downside. » Mere på finanzen.net

Stefan Dräger sees the German chemical sector in decline and speaks of a quiet crisis, because many production plants are shut down or not being restarted. As a supplier of measurement and safety equipment, Dräger is recording revenue declines in the chemical sector but can offset these through growth in other areas. Dräger cites energy prices and bureaucracy as the main reasons for the difficult situation. » Mere på finanzen.net

Drägerwerk has upgraded its full-year targets again in mid and late July, mainly thanks to customs refunds totaling around €22 million. The 2026 EBIT margin is now expected at 6–8% (previously 5.5–7.5%), while revenue growth remains unchanged at 1–5% (currency-adjusted 2–6%). In the first half, currency-adjusted revenue rose 7.7% to €1,603.2 million and EBIT increased to €63.8 million. Investors are speculating, due to the strong H1 figures, about a further target increase ahead of the Q3 results; the editorial team says the stock should be on the watchlist. » Mere på finanzen.net